An interventional study of Fluconazole in Candidiasis, Mycoses and HIV Infections, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Pfizer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fluconazole in Candidiasis — 1 open to participants now, 1 under way, none of them phase 3. Fluconazole · Candidiasis.
Among the 19 studies testing fluconazole in Candidiasis, this one is one of 5 with no phase, and was the 1st registered.
132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.
Browse Candidiasis studies →1 of the 19 studies testing fluconazole in Candidiasis is open now, in 3 countries. Recruiting first, the newest first:
Bochud Pierre-Yves · Sites in Belgium, France, Switzerland
Ages 18+
By country, each count listing its studies:
Fluconazole: first FDA approval 1990 (DIFLUCAN). What it is approved for, and how studies give it, is on its page →
Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 4
First in 1996; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 228 across the 16 interventional studies. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 19 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Candidiasis by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 15 studies in Candidiasis by Pfizer, this one is one of 2 with no phase, and was the 1st registered.
Pfizer’s Candidiasis studies by the year they started, since 1998.
1 of the studies testing fluconazole in Candidiasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03828773Bochud Pierre-YvesPTX3-targeted Antifungal Prophylaxis | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing fluconazole in Candidiasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Candidiasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal therapy or have had unacceptable reactions to conventional antifungal therapy, and who are ineligible for other established fluconazole clinical trial protocols.
Exclusion Criteria
Co-existing Condition:
A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.
A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.
AMENDED:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Jun 1996. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluconazole